TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17304149
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg daily for 6 days
Study: 15085466
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous unfractionated heparin (UFH) for 5 days
Study: 2863541
Drug: Warfarin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin for 3 months
Study: 16871061
Drug: Oral feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feedback
Study: 11499187
Drug: Any feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any feedback (oral or written)
Study: 7840913
Drug: Saquinavir 200
Normalized name: saquinavir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir 200 mg in combination with zidovudine
Study: 25922420
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg oral MDMA
Study: 17578566
Drug: ATP (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP (2 g per dosage)
Study: 17578566
Drug: Adenosine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (1 g per dosage)
Study: 14760130
Drug: Palonosetron (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (various doses)
Study: 11123827
Drug: Weekly doses
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly doses of 400 mg of ferrous sulphate for 4 months
Study: 3881376
Drug: Adjuvant MOPP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant MOPP chemotherapy
Study: 3881376
Drug: New mild
Approvals — FDA: no, EMA: no, PMDA: no
Description: New mild adjuvant chemotherapy VBM (vinblastine, bleomycin, and methotrexate) with ABVD in combined modality and alternating regimens
Study: 22126423
Drug: Alfacalcidol (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (0.03 µg/kg/day) - Monotherapy
Study: 22126423
Drug: Alfacalcidol and
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol and Risedronate (0.05 mg/kg/day) - Polytherapy
Study: 22126423
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (discontinued medications)
Study: 11913800
Drug: E 047/1
Approvals — FDA: no, EMA: no, PMDA: no
Description: E 047/1 (1 mg kg(‐1) in pilot study, 2 mg kg(‐1) or 3 mg kg(‐1) bolus in randomized trial)
Study: 9653596
Drug: Sex hormone
Normalized name: Sex hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex hormone replacement with 17 beta‐estradiol and norethisterone
Study: 8595637
Drug: Ibuprofen lysine
Normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen lysine 400 mg
Study: 2475016
Drug: Prazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (2 mg twice daily)
Study: 26239241
Drug: Self-administered Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered Internet-based intervention protocol (SII)
Study: 30268162
Drug: Aloe Vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe Vera gel
Study: 1727882
Drug: 1% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% silver sulfadiazine cream
Study: 29080520
Drug: Chamomile therapy
Normalized name: Chamomile
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile therapy
Study: 27172423
Drug: Weekly distributed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly distributed bronchoscopy simulation practice
Study: 16554683
Drug: Level 1
Normalized name: PALFORZIA (Level 10) KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level 1 treatment studies in traumatic brain injury (15 studies)
Study: 16554683
Drug: Level 1
Normalized name: PALFORZIA (Level 10) KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level 1 treatment studies in burn rehabilitation (12 studies)
Study: 16554683
Drug: Level 2
Normalized name: True Metrix Control Level 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level 2 treatment studies in spinal cord injury (26 studies)
Study: 16554683
Drug: Level 2
Normalized name: True Metrix Control Level 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level 2 treatment studies in traumatic brain injury (4 studies)
Study: 16554683
Drug: Level 2
Normalized name: True Metrix Control Level 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level 2 treatment studies in burn rehabilitation (2 studies)
Study: 14627846
Drug: Haloperidol (subchronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (subchronic low dose)
Study: 14627846
Drug: Haloperidol (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (higher dose)
Study: 7282603
Drug: 4.1 g
Normalized name: psyllium 4.1 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.1 g omega 3 fatty acids
Study: 7282603
Drug: 8.2 g
Normalized name: SORBITOL 258.2 g in 474 mL ORAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.2 g omega 3 fatty acids
Study: 29368994
Drug: Message to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Message to avoid antipsychotic medications
Study: 29368994
Drug: Actual facility
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Actual facility antipsychotic prevalence
Study: 29368994
Drug: Avoid antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoid antipsychotics message
Study: 15561516
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine treatment for 4 weeks
Study: 15561516
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list control group (continued previous headache treatment)
Study: 15561516
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine treatment
Study: 17932848
Drug: Chloramphenicol 0.25%-betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol 0.25%-betamethasone 0.13% gel three times a day (Group 1)
Study: 16249353
Drug: Paclitaxel (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (200 mg/m² i.v. day 1), carboplatin (AUC 6 i.v. day 1), and etoposide (50 mg/100 mg alternating daily by mouth days 1-10) every 21 days
Study: 9952060
Drug: 0.30 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 g/kg ethanol
Study: 9952060
Drug: 0.60 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.60 g/kg ethanol
Study: 25711322
Drug: HIV RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV RNA <50 copies/mL
Study: 25711322
Drug: HIV RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV RNA between 51 and 400 copies/mL
Study: 25711322
Drug: HCV antibody
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV antibody positivity
Study: 17349088
Drug: n-3-enriched foods
Normalized name: 3-n-butylphthalide
DrugBank: Butylphthalide (DB12749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3-enriched foods (EPA + DHA intake of 1 g/d)
Study: 10993128
Drug: Sertraline (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50-200 mg)
Study: 19160529
Drug: Simvastatin 20-40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20-40 mg/day
Study: 14656784
Drug: Fentanyl 50
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 50 micro g, lockout six‐minute
Study: 14656784
Drug: Fentanyl 25
Normalized name: FENTANYL 25MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 25 micro g, lockout three‐minute
Study: 14656784
Drug: Fentanyl 50
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 50 micro g, lockout three‐minute
Study: 24445560
Drug: Morphine PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine PCA
Study: 1399944
Drug: RP 59500
Normalized name: RP-72
DrugBank: RP-72 (DB17156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP 59500 (1.4, 2.8, 4.6, 7.0, 9.8, 12.6, 16.8, 22.4, 29.4 mg/kg)
Study: 6235453
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (Heptavax‐B), 40 micrograms each, administered in three doses.
Study: 6235453
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (Heptavax‐B).
Study: 31049735
Drug: Different food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different food formulations and processing methods involving meat, wholegrain, fruits and vegetables
Study: 19780244
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy with alkylating agent-based therapies
Study: 8195454
Drug: Flutamide (nonsteroidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (nonsteroidal androgen receptor blocking agent)
Study: 2884455
Drug: Bovine rotavirus
Normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine rotavirus vaccine (RIT 4237), 3 doses administered concurrently with oral or killed polio vaccine.
Study: 2884455
Drug: Placebo/oral polio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/oral polio group (unvaccinated control).
Study: 2884455
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of oral polio vaccine with rotavirus vaccine.
Study: 2884455
Drug: Oral polio
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polio and rotavirus vaccines.
Study: 23392654
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (aspirin and clopidogrel)
Study: 18342111
Drug: Avène thermal
Normalized name: avens extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avène thermal spring water anti burning gel (ATSW gel)
Study: 18342111
Drug: Trolamine cream
Normalized name: METHYL SALICYLATE/TROLAMINE CREAM
DrugBank: Trolamine (DB13747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trolamine cream (Control)
Study: 1381822
Drug: Other antiarrhythmic
Normalized name: Other antiarrhythmics, class I and III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antiarrhythmic drugs
Study: 21114406
Drug: NuLytely(®) (PEG‐3350,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NuLytely(®) (PEG‐3350, sodium chloride, sodium bicarbonate, and potassium chloride solution)
Study: 17689667
Drug: Internet-administered Edinburgh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-administered Edinburgh Depression Scale (EDS)
Study: 10773774
Drug: Weekly group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly group psychotherapy for 4 months
Study: 29803904
Drug: Ixekizumab (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab (160 mg at week 0, 80 mg every 2 weeks up to week 12, and 80 mg every 4 weeks thereafter)
Study: 29803904
Drug: Ixekizumab (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab (after switching from other treatments)
Study: 25726428
Drug: Resistance exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance exercise program + 10 g/day BCAA supplementation
Study: 25369174
Drug: Korean red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean red ginseng (KRG) extract, 1g KRG extract/pouch, twice a day
Study: 30314452
Drug: Extended endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended endocrine therapy to 10 years in postmenopausal subgroup
Study: 30314452
Drug: Extended endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended endocrine therapy to 10 years in ER+ and/or PR+ subgroup
Study: 9286780
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 infusion
Study: 1983321
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg o.m.)
Study: 10594396
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg b.d.)
Study: 17237648
Drug: Long duration,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long duration, high flow rate MUF (group L)
Study: 14725516
Drug: Synacthen Depot
Normalized name: Synacthen Depot
DrugBank: Tetracosactide (DB01284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synacthen Depot 1 mg (1 ml)
Study: 9720545
Drug: Topical urethral
Normalized name: Urethral Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical urethral anesthesia with adjunctive intravenous sedoanalgesia
Study: 9720545
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Topical anesthesia and Sedoanalgesia)
Study: 8158032
Drug: Mefloquine prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine prophylaxis (10 mg/kg initial loading dose)
Study: 3377147
Drug: Intramuscular papaveretum
Normalized name: papaveretum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular papaveretum 0.2 mg/kg
Study: 3377147
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (placebo)
Study: 23446073
Drug: Biofeedback-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback-based cognitive-behavioral treatment (BFB-CBT)
Study: 9773111
Drug: Diltiazem (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (300 mg)
Study: 8196120
Drug: OspA Lyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: OspA Lyme vaccine (10 micrograms, 2 doses)
Study: 8196120
Drug: OspA Lyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: OspA Lyme vaccine adsorbed to alum (10 micrograms, 2 doses)
Study: 31690121
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection with 1% lidocaine and epinephrine (1 mL, 40 mg triamcinolone + 1 mL lidocaine with epinephrine)
Study: 27106967
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 4 g over 1 h, then 1 g per h over six h
Study: 24504445
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 45 mg/m² every 4 weeks
Study: 24504445
Drug: Capecitabine 1000
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m² twice daily, day 1-14 every 3 weeks
Study: 22776045
Drug: CC with
Normalized name: BD Syringe 5cc with Needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC with a bolus calculator
Study: 20660038
Drug: 1 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg cosyntropin test
Study: 18486512
Drug: Baseline alanine
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baseline alanine aminotransferase (ALT) levels of 17-22 mg/dl
Study: 18486512
Drug: Baseline alanine
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baseline alanine aminotransferase (ALT) levels of 23-38 mg/dl
Study: 18486512
Drug: Baseline alanine
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baseline alanine aminotransferase (ALT) levels greater than 38 mg/dl
Study: 16133900
Drug: Project SPORT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Project SPORT (brief consultation and prescription with a mailed reinforcing follow-up flyer)
Study: 12471182
Drug: Alteplase (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (2 mg/2 mL) administered into the lumen of the central venous catheter, with a maximum of two doses allowed to dwell for up to 120 minutes each.
Study: 2106087
Drug: Dexamethasone (Dex)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (Dex) 4 mg i.v. administered 3 h before GHRH
Study: 2106087
Drug: Clonidine administration
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine administration 300 micrograms p.o. with Dex 8 mg
Study: 2106087
Drug: Clonidine administration
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine administration 300 micrograms p.o. with Dex 22 mg
Study: 17324283
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care approach including contracting, 'Problem Solving Treatment', antidepressant algorithm, and manual-guided self-help
Study: 2511802
Drug: Fleroxacin 600
Normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 600 mg once daily for 7 days
Study: 2511802
Drug: Fleroxacin 800
Normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 800 mg once daily for 7 days
Study: 2511801
Drug: Fleroxacin 800
Normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 800 mg
Study: 337916
Drug: Three-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug regimen (cyclophosphamide, methotrexate, fluorouracil)
Study: 337916
Drug: Five-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-drug regimen (vincristine sulfate, prednisone, cyclophosphamide, methotrexate, fluorouracil)
Study: 337916
Drug: Five-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-drug regimen after progression of disease
Study: 25035069
Drug: SFC 50/250
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC 50/250 μg Rotacaps/Rotahaler (S)
Study: 25035069
Drug: SFC 50/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC 50/100 μg Rotacaps/Rotahaler (L)
Study: 25035069
Drug: SFC at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC at both doses and via both inhalers
Study: 29797907
Drug: Tongdu Tiaoshen
Normalized name: MENTHOL 3 g TRANSDERMAL PATCH [TIANHE GUBEN YAOSHEN TIE GAO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongdu Tiaoshen needles therapy
Study: 26975954
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg daily for 2 weeks)
Study: 11333096
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no agent)
Study: 23902782
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1500 mg/d during pregnancy)
Study: 12748567
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CRM and vestibular rehabilitation (VR)
Study: 487688
Drug: Atenolol, 50
Normalized name: Atenolol, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, 50 mg daily
Study: 14982562
Drug: Propofol 60
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 60 mg ml(-1)
Study: 7536155
Drug: Octreotide 0.1
Normalized name: octreotide 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 0.1 mg subcutaneously 120 and 30 min before EST and four hours after
Study: 25404215
Drug: Text message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text message intervention (SMS sent at h48, D7, D15 and monthly)
Study: 2654467
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (control group)
Study: 20886733
Drug: Transcranial bitemporal
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial bitemporal magnetotherapy (TcMT) combined with reduced basic therapy (driptan 2.5 mg twice a day)
Study: 20886733
Drug: Placebo TcMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo TcMT with basic therapy
Study: 16648332
Drug: Sertraline (N=14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (N=14 overweight and obese subjects)
Study: 12953327
Drug: Transdermal delivery
Normalized name: nitroglycerin 5 mg in 1 d TRANSDERMAL PATCH [Nitroglycerin Transdermal Delivery System]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal delivery of reproductive steroids
Study: 22453589
Drug: Zinc citrate
Normalized name: Zinc Citrate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc citrate 50 mg and phytase 3,000 PU
Study: 22453589
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate 10 mg
Study: 12385443
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg SP-303
Study: 20582906
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg Ginkgo extract (EGb 761)
Study: 18026906
Drug: Weekly gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly gemcitabine (125 mg/m(2)) with cisplatin (40 mg/m(2)) and pelvic radiotherapy
Study: 10609984
Drug: d-amphetamine (indirect
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (indirect dopamine agonist)
Study: 2002251
Drug: Digital intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital intradermal injections of histamine
Study: 2002251
Drug: Digital intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital intradermal injections of substance P
Study: 2002251
Drug: Digital intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital intradermal injections of calcitonin gene‐related peptide
Study: 2002251
Drug: Digital intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital intradermal injections of compound 48/80
Study: 1694913
Drug: Metoprolol (100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100-300 mg/day)
Study: 1694913
Drug: Pindolol (5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (5-15 mg/day)
Study: 26684670
Drug: Comparison treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison treatment